Camp4 Therapeutics Corp Logo

Camp4 Therapeutics Corp

Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.

CAMP | US

Overview

Corporate Details

ISIN(s):
US13463J1016
LEI:
Country:
United States of America
Address:
ONE KENDALL SQUARE, 2139 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Camp4 Therapeutics Corp. is a clinical-stage biopharmaceutical company pioneering a novel approach to programmable therapeutics. The company develops RNA-based treatments by leveraging its proprietary Regulatory RNA Actuator Platform (RAP Platform™). This platform is designed to discover and create RNA Actuators, a class of antisense oligonucleotide (ASO) therapies that selectively target and upregulate the expression of specific genes. By increasing the output of essential proteins, Camp4 aims to address the root cause of genetic diseases. The company's therapeutic pipeline is initially focused on developing treatments for rare metabolic and central nervous system (CNS) disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Camp4 Therapeutics Corp filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Camp4 Therapeutics Corp

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Camp4 Therapeutics Corp via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

TiumBio Co., Ltd. Logo
Clinical-stage biopharma developing therapies for rare diseases, gynecology, and hemophilia.
South Korea
321550
TMS Co., Ltd Logo
Develops small molecule drugs from natural compounds for the global pharmaceutical market.
Japan
4891
Together Pharma Ltd. Logo
Researches and produces medical cannabis products for domestic and European patients.
Israel
TGTR
Tonix Pharmaceuticals Holding Corp. Logo
Develops therapies and vaccines for complex conditions and public health challenges.
United States of America
TNXP
A pharmaceutical specialist in drugs for renal, skin, and allergic diseases.
Japan
4551
Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW

Talk to a Data Expert

Have a question? We'll get back to you promptly.